Patents by Inventor Jörg STOCKHAUS

Jörg STOCKHAUS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kv1.3 potassium channel antagonists
    Patent number: 10800815
    Abstract: The present disclosure provides compounds that selectively bind and inhibit potassium channel Kv1.3.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: October 13, 2020
    Assignee: Select ION Therapeutics GMBH
    Inventors: Andreas Klostermann, Jörg Stockhaus
  • KV1.3 POTASSIUM CHANNEL ANTAGONISTS
    Publication number: 20190375795
    Abstract: The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel Kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 12, 2019
    Inventors: Andreas Klostermann, Jörg Stockhaus
  • Kv1.3 potassium channel antagonists
    Patent number: 10370413
    Abstract: Compounds which selectively bind to and inhibit the activity of the potassium channel Kv1.3 are described. Pharmaceutical compositions comprising such compounds and the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection are also described.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 6, 2019
    Assignee: cgtx-Peptide Development GmbH
    Inventors: Andreas Klostermann, Jörg Stockhaus
  • Kv1.3 Potassium Channel Antagonists
    Publication number: 20170137470
    Abstract: The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel Kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.
    Type: Application
    Filed: May 7, 2015
    Publication date: May 18, 2017
    Inventors: Andreas KLOSTERMANN, Jörg STOCKHAUS